Table 7.
Growth outcomes in girls of the near-adult height subgroup
| Diagnosis | No.a | rhGH start | Puberty onseta | NAH | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Age, y | Ht-SDS | Age, y | Ht-SDS | Prepubertal gain | Age, y | Ht-SDS | Pubertal gaina | Total gain | ||
| IGHD | 1186 | 7.6 (3.8 to 11.0) |
−3.62 (−5.41 to −2.46) |
11.9 (10.3 to 14.3) |
−1.13 (−2.35 to 0.19) |
2.45 (1.37 to 4.37) |
16.1 (14.5 to 18.7) |
−1.47 (−3.07 to 0.07) |
−0.18 (−1.05 to 0.70) |
2.07 (0.80 to 4.24) |
| NSD | 58 | 8.8 (5.0 to 11.1) |
−3.33 (−4.88 to −2.40) |
12.2 (10.9 to 14.5) |
−1.39 (−2.22 to 0.16) |
2.12 (1.30 to 3.74) |
15.7 (14.2 to 17.5) |
−1.40 (−2.73 to −0.24) |
−0.24 (−1.17 to 0.65) |
1.90 (0.91 to 2.96) |
| congGHD | 201 | 5.4 (1.3 to 9.3) |
−4.10 (−6.45 to −2.21) |
12.4 (10.0 to 14.5) |
−1.02 (−2.36 to 0.68) |
3.26 (2.16 to 5.86) |
16.8 (14.9 to 19.0) |
−1.13 (−2.81 to 0.61) |
−0.13 (−1.06 to 0.75) |
3.10 (1.32 to 5.16) |
| CP | 121 | 8.4 (4.6 to 11.3) |
−2.14 (−3.95 to −0.35) |
13.1 (11.1 to 15.9) |
0.03 (−1.69 to 1.58) |
1.90 (1.10 to 4.16) |
17.8 (15.5 to 20.6) |
−0.05 (−1.73 to 1.72) |
0.25 (−0.80 to 1.16) |
2.26 (0.59 to 4.08) |
| MB | 59 | 8.1 (4.9, 10.9) |
−2.52 (−4.38 to −0.63) |
10.8 (9.4 to 13.5) |
−1.81 (−2.92 to −0.73) |
1.21 (−0.21 to 2.59) |
16.6 (14.5 to 19.4) |
−2.20 (−4.14 to −0.37) |
−1.02 (−1.72 to −0.18) |
0.40 (−0.82 to 1.56) |
| OCT | 98 | 8.7 (5.6 to 11.6) |
−2.24 (−4.11 to −0.45) |
12.9 (8.9 to 16.4) |
−1.13 (−2.46 to 0.73) |
1.85 (0.54 to 3.05) |
17.1 (14.6 to 20.3) |
−0.97 (−2.89 to 0.87) |
−0.29 (−1.34 to 1.08) |
1.26 (−0.42 to 2.99) |
| ECM | 44 | 9.2 (6.7 to 11.0) |
−1.97 (−3.52 to −0.85) |
11.9 (10.3 to 13.5) |
−1.10 (−2.58, 0.15) |
1.00 (0.16 to 1.95) |
16.3 (14.9 to 19.9) |
−1.68 (−3.38 to −0.17) |
−1.09 (−1.66 to −0.48) |
0.28 (−0.76 to 1.76) |
| ISS | 129 | 8.1 (3.8 to 11.5) |
−3.72 (−4.79 to −2.80) |
11.8 (10.5 to 13.9) |
−1.74 (−2.37, −0.34) |
2.10 (1.30 to 2.61) |
16.2 (14.7 to 18.7) |
−2.17 (−3.67 to −0.62) |
−0.34 (−0.84 to 0.24) |
1.62 (0.56 to 2.85) |
| TS | 1631 | 8.0 (4.5 to 11.2) |
−3.28 (−4.43 to −2.14) |
13.2 (11.4 to 15.0) |
−1.38 (−2.55, −0.29) |
1.84 (1.13 to 2.72) |
16.7 (15.0 to 18.5) |
−2.18 (−3.51 to −0.85) |
−0.77 (−1.45 to −0.04) |
1.07 (0.10 to 2.12) |
| PWS | 82 | 7.4 (4.3 to 10.1) |
−2.48 (−4.39 to −0.82) |
10.8 (8.2 to 13.3) |
−0.24 (−1.44 to 0.72) |
2.30 (0.49 to 4.42) |
16.8 (14.5 to 19.1) |
−1.41 (−3.14 to 0.14) |
−0.86 (−2.02 to 0.18) |
1.35 (−0.75 to 2.60) |
| OS | 145 | 7.5 (4.0 to 10.9) |
−4.27 (−5.90 to −2.55) |
12.2 (10.3 to 15.0) |
−1.90 (−2.81 to −0.43) |
2.37 (1.38 to 3.52) |
16.1 (14.6 to 18.4) |
−2.46 (−3.92 to −0.96) |
−0.69 (−1.52 to 0.30) |
1.64 (0.44 to 3.04) |
| SGA | 185 | 7.6 (4.1 to 10.1) |
−3.72 (−4.94 to −2.83) |
11.1 (9.2 to 13.2) |
−1.57 (−2.60 to −0.52) |
2.16 (1.24 to 3.34) |
15.4 (14.3 to 17.0) |
−2.10 (−3.55 to −0.88) |
−0.36 (−1.30 to 0.33) |
1.57 (0.59 to 2.76) |
| CRF | 49 | 9.3 (5.2 to 13.3) |
−3.76 (−6.13 to −1.85) |
12.7 (11.3 to 16.7) |
−2.80 (−3.89 to −0.31) |
1.79 (−0.27 to 3.22) |
16.5 (15.1 to 19.7) |
−2.18 (−4.79 to −0.24) |
−0.28 (−1.45 to 1.47) |
1.59 (−0.14 to 3.30) |
| Other | 164 | 8.1 (4.5 to 10.9) |
−3.67 (−5.19 to −2.45) |
13.1 (11.2 to 15.0) |
−1.43 (−2.88 to −0.04) |
2.34 (1.34 to 4.02) |
16.3 (14.6 to 18.8) |
−1.96 (−3.94 to −0.20) |
−0.23 (−1.47 to 0.68) |
1.67 (−0.02 to 3.55) |
Data are presented as median (10th-90th percentile) unless noted otherwise.
Abbreviations: congGHD, congenital GHD; CP, craniopharyngioma; CRF, chronic renal failure; ECM, extracranial malignancy; GHD, growth hormone deficiency; Ht-SDS, height SD score; IGHD, idiopathic GHD; ISS, idiopathic short stature; MB, medulloblastoma; NAH, near-adult height; NSD, neurosecretory dysfunction; OCT, other cranial tumors; OS, other syndromes; PWS, Prader-Willi syndrome; rhGH, recombinant human growth hormone; SGA, small for gestational age; TS, Turner syndrome.
For puberty onset and pubertal gain at NAH, N = 434 (IGHD), 17 (NSD), 74 (congGHD), 57 (CP), 17 (MB), 33 (OCT), 13 (ECM), 47 (ISS), 777 (TS), 17 (PWS), 56 (OS), 57 (SGA), 15 (CRF), and 42 (Other).